Fig 2: S100P is down-regulated in the mid-secretory phase endometrium of participants from GnRH-ant group. A S100P gene expression in different groups from microarray data. B Immunohistochemical detection of S100P in the endometrium from the different groups, magnified in 200 times and the scale bar represents 50um. a. Negative control, b. Natural cycle control, c. GnRH antagonist group, d. GnRH agonist group; quantified in (C). D Location of S100P in endometrium by co-localization with vimentin and keratin. Red: S100P; Green: vimentin (b) and cytokeratin (f); Blue: nucleus. The scale bar represents 50um. E Western blot results of S100P and HOXA10 protein expression in endometrium from the natural cycle, GnRH-ant and GnRH-a groups. F Quantification of S100P protein expression. G Quantification of HOXA10 protein expression. *P < .05, **P<.01, ***P<.001

Fig 3: The effect of S100P on invasion and migration of breast cancer cells in vitro. (A,B) Invasive ability was significantly decreased in T47D cells after S100P was knocked down (p < 0.001). (C,D) Invasive ability was significantly decreased in SK-BR-3 cells after S100P was knocked down (p < 0.01). (E,F) Migrative ability was decreased in T47D cells after S100P was knocked down (48 h, p < 0.05) (n = 7 per group). (G,H) Migrative ability was decreased in SK-BR-3 cells after S100P was knocked down (48 h, p < 0.01) (n = 14 per group). *p < 0.05; **p < 0.01; ***p < 0.001.

Fig 4: The combination of S100P and E-cadherin molecular profiles defines subgroups with different clinical outcomes. a Representative images of S100P and E-cadherin protein expression detected by immunohistochemistry in a gastric carcinoma TMA. Manual annotation of each histological sample was performed by an experienced pathologist and cases were dichotomised using a simplified classification scheme considering retaining (graded as 3+) versus loss of marker from 0 to 2+. b Kaplan-Meier curves showing the probability of overall survival for patients with GC according to S100P expression. c Kaplan-Meier curves showing the probability of overall survival for patients with GC according to E-cadherin expression, indicating that loss of E-cadherin expression associates with a poorer overall survival. d Survival plot depicting the overall survival of patients according to four molecular phenotypes defined by the loss/retention of E-cad and S100P expression. Although not statistically significant, patients presenting the E-cadloss/S100Pret molecular phenotype follow a survival curve under that of all other patients

Fig 5: Increased S100P expression during FSK-induced syncytialization of TSCT cells. (A) Quantification of S100P mRNA expression in ST(2D)-TSCT cells measured on D3 and D6. The mean values ± SEMs (normalized to GAPDH) are shown. D3: day 3, D6: day 6. *p=0.0110; ***p=0.0002; ****p<0.0001. (B) Western blotting analysis of S100P and 11ß-HSD2 in ST(2D)-TSCT cells measured on D3 and D6. Semiquantitative analysis of S100P and 11ß-HSD2 protein expression normalized to GAPDH (n=3). **p=0.0073; ***p=0.0006; ****p<0.0001. (C) Immunofluorescence staining of S100P (red), E-cadherin (green), ß-hCG (green) and Hoechst staining (blue) in human TSCT, ST(2D)-TSCT (D6) and ST(3D)-TSCT cells (D6). White arrows indicate cytoplasmic S100P expression, and yellow arrows represent nuclear S100P expression. Representative images from three independent experiments are shown. Scale bar, 20 µm. (D) Measurement of the secreted S100P levels in human TSCT and ST(2D)-TSCT cultures (D3 and D6) by ELISA. The levels were measured in three independent experiments. ****p<0.0001. (E) Measurement of secreted ß-hCG levels in human TSCT and ST(2D)-TSCT cultures (D3 and D6) as assessed by ELISA. The levels were measured in three independent experiments. *p=0.0283; ****p<0.0001.